Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued to investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Trevena in a research report on Thursday, November 14th.

Trevena Price Performance

TRVN stock opened at $1.77 on Thursday. The stock has a market capitalization of $1.52 million, a P/E ratio of -0.04 and a beta of 1.05. Trevena has a fifty-two week low of $1.13 and a fifty-two week high of $17.50. The business has a 50-day moving average of $1.70 and a 200-day moving average of $3.03.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) EPS for the quarter. The company had revenue of $0.28 million during the quarter. Equities analysts expect that Trevena will post -23.04 EPS for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.